FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions discloses a pharmaceutical composition and a kit containing type II anti-CD20 antibodies and a proteasome inhibitor applicable in treating cancer expressing CD20. Also, the group of inventions refers to using type II anti-CD20 antibodies for obtaining a drug preparation applicable for treating cancer expressing CD20 in a combination with the proteasome inhibitor.
EFFECT: group of inventions is characterised by using the antibodies possessing high antibody-dependent cell-mediated cytotoxicity and efficacy in the therapy of cancer diseases.
13 cl, 3 dwg, 4 tbl, 3 ex
